FORGE Life Science President & CEO, Lillian Chiang, is selected to join Springboard Enterprises Health Innovation Hub 2018: Life Sciences Track cohort for women entrepreneurs. Read more
FORGE Life Science completes Milestone 1 in agreement with BioArdis, LLC, securing second tranche of in-kind services investment.
FORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.
FORGE Life Science President & CEO, Lillian Chiang, presents “Targeting Host-cell Metabolism to Address Multiple Intracellular Pathogens” at the 2017 Chemical and Biological Defense Science & Technology Conference, Long Beach, CA. Read more
FORGE Life Science secures a second in-kind services investment from BioArdis, LLC, expanding FORGE medicinal chemistry and DMPK research resources to include BioDuro, global provider of contract research services.
FORGE Life Science Board of Directors meeting with new external members Richard J. Whitley, Brian Pusch, Steven Holtzman joining Founders Thomas E. Shenk and Lillian W. Chiang on the Board.
FORGE Life Science President & CEO, Lillian Chiang, presents at 9th Annual Biotech Showcase 2017 investor conference in San Francisco, CA.
FORGE Life Science Board Chairman, Thomas Shenk, presents at China Renaissance’s 4th Healthcare and Life Sciences Leadership Summit in Shanghai, China.
BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more.
BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more
